Scientific Abstracts: Thoracic, Renal, and Bone
Objective: Thermal ablation of renal tumors is safe and efficacious, but has one major limitation: tumor size. Tumors less than 3 cm may be treated with thermal ablation alone, but with larger masses, there is a significant increase in the risk of post-procedure complications and recurrence. Treatment of large renal masses with cryoablation has been attempted with mixed results. Combined embolization and radiofrequency ablation has recently shown encouraging results. We report on the combined use of microwave ablation and selective transarterial embolization to treat large renal masses in a single session.
Methods: After obtaining IRB approval, a review of the medical record between 10/16-8/19 was performed. Patients with renal tumors who underwent combined selective transarterial embolization and microwave ablation (STE-MWA) were assessed retrospectively. Patient demographic information, intraoperative, postoperative, and follow-up data was recorded.
Results: Between 10/16-8/19, 11 patients who underwent STE-MWA were identified. The mean age of the cohort was 73 years (SD 9.6), with 64% male patients, an average BMI of 26.5 (SD 4.5), and an average Charleston Comorbidity Index of 6.7 (SD 2.3). Nine of eleven tumors were identified as Clear Cell Carcinoma, one as Papillary Carcinoma, and one as oncotic neoplasm. Average tumor size was 4.5 cm (SD 1.7), with an average RENAL score of 8.5 (SD 1.6). Technical success was achieved in all patients, and in all cases, ablation and embolization were performed on the same day. The only related post procedure complication was a groin hematoma noted in one patient, and 6/11 patients were discharged on the same day. Post-procedure surveillance was performed with either CT or MRI. Average follow up was 375.7 days (N=10, SD 187 Range 100-634 Days), with no patients showing evidence of recurrence to date.
Please replace the conclusion section with the following:
Combined single-session STE-MWA is technically feasible, safe, and efficacious in treating large renal tumors in a cohort of 11 patients with no recurrence to date. A larger prospective trial with long-term follow-up is needed to further assess the viability of this technique.
Conclusions: Combined single-day STE-MWA is technically feasible, safe, and efficacious in treating large renal tumors in a cohort of 11 patients with no recurrence to date. A larger prospective trial with long-term follow-up is needed to further assess the viability of this technique.